AI assistant
Sending…
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2024
Jan 3, 2024
30849_dirs_2024-01-03_925bb923-2722-4f30-b48c-1b39ce70ed2d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-12-29
Reporting Person: Smith Hunter C (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-12-29 | Common Stock | M | 10500 | $6.88 | Acquired | 71906 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-12-29 | Stock Option (Right to Buy) | $6.88 | M | 10500 | Disposed | 2027-08-08 | Common Stock (10500) | Direct |
Footnotes
F1: The stock options is fully vested.
More from RHYTHM PHARMACEUTICALS, INC.
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 3